亚洲在线日韩伦理片,96精品国产AⅤ一区二区,青鸟影视网,yy黄色频道,国内精品久久久精品AV电影院

 HANGZHOU, China, Sept. 5, 2025 /PRNewswire/ -- Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative?antibody–drug conjugate (ADC) targeting receptor ty...

 SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- These days, the first prescriptions of FUTUONING (fovinaciclib citrate capsules) were issued by more than ten hospitals acrossChina, including Fudan University Shanghai Cancer Center, Cancer Hospital of the Chinese Academy of Medical Sciences, The First Af...

 LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced that the Company plans to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. Jared Bearss...

 SHANGHAI and JERSEY CITY,?N.J., Sept. 2, 2025 /PRNewswire/ --?Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS? (denosumab-nxxp) injection 60 mg/mL and BILPREVDA? (denosumab-nxxp) injection 120 mg/1.7 ...

 -??????? The program focuses on antibiotic resistance in urinary tract infections (UTI-DR), with applications open untilNovember 20; final awardees to be announced inAugust 2026 -??????? Selected researchers will receive up to USD 600,000 in research funding, along with access to Seegene's syndro...

 Secures third contract this year, reinforcing global competitiveness?and expanding strategic partnerships SEOUL, South Korea and SYRACUSE, N.Y., Sept. 2, 2025 /PRNewswire/ -- LOTTE BIOLOGICS (CEOJames Park) today announced that it has entered a late-stage to commercial contract manufacturing par...

 * 26 scientific abstracts, including two oral presentations, demonstrate?UCB's ongoing commitment to advancing research for people living with epilepsies * Data include an open-label extension study describing the long-term safety of?FINTEPLA?▼?(fenfluramine)[1] and global functioning in chil...

 SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 a...

 HONG KONG, Aug. 28, 2025 /PRNewswire/ --?AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are ...

 HONG KONG, Aug. 27, 2025 /PRNewswire/ -- On 27 August, Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended30 June 2025. In the first half of 2025, Fosun actively captured macroeconomic trends, maintained a clear strategic focus, and leverag...

 * Abbott's?denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais * This approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches inMalaysia and Indi...

 Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities WASHINGTON, Aug. 26, 2025 /PRNewswire/ -- Neopharma Technologies Limited ("Neopharma") today announced it hasentered into a global software licensing and collaboration agreement with Zhejian...

 SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390....

 SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fin...

 NANJING, China, Aug. 25, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data.This milestone endows...

 SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment ofFrancis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and ...

 * The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 * DEEs ar...